Stockscreener 앱 받기
9.00
0.22%
-0.02
전일 마감가:
$9.02
열려 있는:
$9.2308
하루 거래량:
7,642
Relative Volume:
0.23
시가총액:
$59.22M
수익:
$43.77M
순이익/손실:
$-35.04M
주가수익비율:
-2.7674
EPS:
-3.2521
순현금흐름:
$-5.51M
1주 성능:
+0.00%
1개월 성능:
-0.99%
6개월 성능:
+18.04%
1년 성능:
-10.47%
1일 변동 폭
$8.81
$9.2308
1주일 범위
$8.57
$9.27
52주 변동 폭
$6.4652
$12.74
Xilio Therapeutics Inc Stock (XLO) Company Profile
명칭
Xilio Therapeutics Inc
전화
617-833-1027
주소
828 WINTER STREET, WALTHAM
Compare XLO vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
XLO
Xilio Therapeutics Inc
|
9.00 | 60.73M | 43.77M | -35.04M | -5.51M | -3.2521 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Xilio Therapeutics Inc Stock (XLO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-06 | 개시 | Leerink Partners | Outperform |
| 2022-12-21 | 개시 | Chardan Capital Markets | Buy |
| 2022-01-10 | 개시 | H.C. Wainwright | Buy |
| 2021-11-16 | 개시 | Cowen | Outperform |
| 2021-11-16 | 개시 | Guggenheim | Buy |
| 2021-11-16 | 개시 | Morgan Stanley | Overweight |
| 2021-11-16 | 개시 | Raymond James | Outperform |
모두보기
Xilio Therapeutics Inc 주식(XLO)의 최신 뉴스
Xilio (XLO) Results and Estimates: Profit Per Share Surpasses Its Benchmark in Latest Trading; Closing Response: The Stock Gains 0.11% at the ClosePost-Announcement Reaction - vinanet.vn
Short Interest in Xilio Therapeutics, Inc. (NASDAQ:XLO) Expands By 58.8% - MarketBeat
Weekly Recap: Xilio (XLO) Q2 revenue jump and FDA IND cleared for XTX501 - TradingView
StemPoint group (XLO) discloses 9.5% Xilio Therapeutics stake via warrants - Stock Titan
Xilio Therapeutics earnings beat by $0.25, revenue topped estimates - Investing.com Canada
Xilio Therapeutics (NASDAQ:XLO) Announces Earnings Results, Beats Estimates By $0.26 EPS - MarketBeat
Xilio Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Xilio Therapeutics Q2 Results: Sales up 131% YoY to $18.7M - scanx.trade
Xilio Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Xilio Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Form 8K Xilio Therapeutics Inc For: 12 August By Investing.com - Investing.com Canada
Xilio Therapeutics, Inc. 2Q 2026: Revenue $18.7M, EPS $(0.33) — 10-Q Summary - TradingView
Xilio Therapeutics reports Q2 2026: $18.7M collaboration revenue, $6.4M net loss, cash $136.0M - TradingView
Xilio Therapeutics (XLO) lifts collaboration revenue and trims net loss in 2026 - Stock Titan
Xilio Therapeutics Reports $18.7 Million Q2 Revenue and FDA Clearance for XTX501 - Quiver Quantitative
Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates - The Manila Times
Xilio Therapeutics Reports Second Quarter 2026 Financial Results And Provides Pipeline And Business Updates - TradingView
Xilio net loss narrows to $6.4 million in Q2 FY26; revenue more than doubles to $18.7 million - Bitget
Xilio Therapeutics (XLO) Holds Steady at $9.18 as Biotech Stock Consolidates Near SupportMomentum Factor - dars.gov.et
Xilio Therapeutics Inc (XLO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Xilio Therapeutics (XLO) Expected to Announce Earnings on Thursday - MarketBeat
XLO Q2'26 Earnings: revenue estimate is 12.72M USD - TradingView
XLO Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost DisciplineEPS Surprise History - Vinanet
XLO|Xilio Therapeutics Inc|Price:9.110|Chg%:+0.030 - TradingKey
Xilio Therapeutics Inc (XLO) Cash Flow - TradingKey
Xilio Therapeutics Inc (XLO) Balance Sheet - TradingKey
Xilio Therapeutics Inc (XLO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Xilio Therapeutics Inc (XLO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Xilio Therapeutics (XLO) Surges 5%: Key Levels to Watch After Breakout MoveRatio Spread Trade - dars.gov.et
Xilio Therapeutics Inc (XLO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Xilio Therapeutics Inc (XLO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Xilio Therapeutics Inc (XLO) Income Statement - TradingKey
XLO|Xilio Therapeutics Inc|Price:9.132|Chg%:+0.482 - TradingKey
Xilio Therapeutics, Inc. Revenue Breakdown – NASDAQ:XLO - TradingView
Xilio Therapeutics, Inc. (XLO) Stock Price, News, Quote & History - Yahoo! Finance Canada
Price to earnings forward of Xilio Therapeutics, Inc. – NASDAQ:XLO - TradingView
XLO Q1 2026 Earnings: Narrower Loss Surprises, Stock Dips on Limited Revenue ProgressProduct Revenue Analysis - Vinanet
Xilio Therapeutics (XLO) Holds Near Support After Modest DeclineRTH Profile - dars.gov.et
Xilio Therapeutics (XLO) Holds Steady Near Resistance – Biotech Stock in Tight RangeInsider Selling Alerts - dars.gov.et
XLO Stock Price, Quote & Chart - ChartMill
Xilio Therapeutics (XLO) Slides 2% as Biotech Stock Tests Key Support LevelsTPO Profile - vinanet.vn
Enterprise value to EBIT forward of Xilio Therapeutics, Inc. – NASDAQ:XLO - TradingView
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Xilio lures three new employees with 107,060 stock options - Stock Titan
Xilio Therapeutics (XLO) Slides as Biotech Sector Headwinds PersistVolume Profile - dars.gov.et
Price to sales forward of Xilio Therapeutics, Inc. – NASDAQ:XLO - TradingView
Xilio Therapeutics, Inc.(NasdaqCM:XLO) added to Russell Microcap Value Benchmark Index - marketscreener.com
Enterprise value to EBITDA forward of Xilio Therapeutics, Inc. – BOATS:XLO - TradingView
Xilio Therapeutics appoints Ben Harshbarger as chief legal officer By Investing.com - Investing.com Nigeria
Xilio Therapeutics, Inc. Announces Appointment of Ben Harshbarger as Chief Legal Officer - marketscreener.com
Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer - citybiz
Xilio Therapeutics Inc (XLO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.86%
0.31%
자본화:
|
볼륨(24시간):